Continuous theta burst stimulation to the frontal pole durably decreases medial frontoamygdala connectivity.

Int Rev PsychiatryJun 30, 2026 (epub)
Clinical ResearchPsychiatry

Kevin C Bickart, Alice Hsu, Daniel M McCalley et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial investigated the effects of continuous theta burst stimulation (cTBS) to the frontal pole in 17 participants with alcohol use disorder. The study found that real cTBS significantly decreased connectivity between the frontal pole and the medial amygdala, with this effect persisting for one month post-treatment. The reduction was most notable in individuals with higher baseline connectivity.

Key findings

  • Real cTBS decreased connectivity between the frontal pole and medial amygdala compared to Sham.
  • The reduction in connectivity was durable, confirmed at one month post-treatment.
  • The effect was most pronounced in participants with the highest baseline connectivity.

Why it matters

Understanding the modulation of amygdala connectivity through the frontal pole may inform future therapeutic strategies for affective disorders, particularly those characterized by amygdala dysregulation.

Source

PubMed · PMID 42379239

Published in Int Rev Psychiatry. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.